FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Royal Chemical Inspection Finds CGMP Violations

FDA warns East Stroudsburg, PA-based Royal Chemical Company about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Medical Devices

Multiple Abbott i-STAT Test Violations

FDA warns Ottawa, Canada-based Abbott Point of Care about multiple violations in its manufacturing of the i-STAT cTnI test cartridges to measure cardi...

Biologics

FDA OKs 2nd Covid Booster for Some People

FDA says some elderly and immunocompromised people are now eligible for a second Moderna or Pfizer BioN/Tech Covid vaccine booster as part of a new si...

latest-news-card-1
Human Drugs

Lessons Learned from Rare Disease Trials During Covid

FDA researchers describe two lessons learned from rare disease clinical trials during the Covid-19 pandemic and their applicability to future trials.

latest-news-card-1
Human Drugs

OND Expands Regulatory Science Research

CDER Office of New Drugs Research Program associate director Laura Jaeger describes the regulatory science research the program has funded.

latest-news-card-1
Human Drugs

EUA Granted for Azure Biotechs OTC Covid Test

FDA issues Azure Biotech an emergency use authorization for the Azure Fastep Covid-19 Antigen Pen Home Test.

latest-news-card-1
EIRS/483s

IntelGenx NDA Approved for Migraine Film

FDA approves an IntelGenx 505(b)(2) NDA for RizaFilm VersaFilm (rizatriptan benzoate) for treating acute migraine.

Medical Devices

BlackSwan Vascular PMA for Arterial Hemorrhage OKd

FDA approves a BlackSwan Vascular PMA for its Lava Liquid Embolic System for treating peripheral arterial hemorrhage.

latest-news-card-1
Human Drugs

Intarcia Raises NDA Advisory Committee Issues

Hogan Lovells attorney David Fox says Intarcia has several concerns about the fairness of an advisory committee meeting that the company agreed could ...

latest-news-card-1
Human Drugs

GSK Plans NDA for Antibiotic Gepotidacin

GSK says it will submit an NDA by 6/30 for antibiotic gepotidacin and its use in treating uncomplicated urinary tract infections.